PCV44 RELATIONSHIP BETWEEN THE OBESITY PARADOX AND HEALTH CARE EXPENDITURES IN SUBJECTS WITH CARDIOVASCULAR DISEASE USING THE MEDICAL EXPENDITURE PANEL SURVEY  by Suh, HS & Doctor, JN
patients or for patients with CHD, and patients of control group
were in routine clinical practice. All patients were observed
during 12 months. Economic efﬁciency in both cases was evalu-
ated on the basis of “cost of illness” and “cost-effectiveness”
analysis. RESULTS: In hypertensive patients we received the
following results. The cost-efﬁciency ratio for decreasing blood
pressure on 1% was $216.6 in the treatment group and $1179 in
the control group. The results of patients’ education in CHD
patient were the following: The cost-efﬁciency ratio for decreas-
ing angina attacks frequency on 1% was S974 in treatment group
and 2838$ in control group. The cost-efﬁciency ratio for decreas-
ing cholesterol on 1% was $2857 in the treatment group and
S4365 in the control group. The cost-efﬁciency ratio for decreas-
ing blood pressure on 1% was $1606 in the treatment group and
$9316 in the control group. CONCLUSION: Educational pre-
ventive technologies for patients with cardiovascular diseases are
cost-effective over a one-year period.
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OBJECTIVE: Diagnosis of coronary artery disease (CAD) in
China using coronary angiography (CA) is challenging due to
high disease prevalence and limited resources. It has been esti-
mated that up to 50% of Chinese patients are negative for CAD
upon CA. Coronary CT Angiography (CTA) may provide an
opportunity to minimize unnecessary invasive diagnostic proce-
dures and increase patient access to diagnosis of CAD in a
cost-effective manner. This study was conducted to evaluate the
potential costs and efﬁciency of utilizing CTA in combination
with CA to optimize diagnosis and care of patients with sus-
pected CAD in China. METHODS: We conducted a cost-
consequences analysis from the perspective of Fuwai Hospital in
Beijing. We developed a decision-analytic model comparing a
diagnostic strategy of CA only with a strategy of CTA in com-
bination with CA for patients with low to moderate pre-test
probability (based on Duke Clinical Score) of signiﬁcant disease.
All CA-positive patients were assumed to receive percutaneous
coronary intervention (PCI). CTA diagnostic accuracy data and
cost estimates were obtained from Fuwai Hospital and other
inputs were derived from the published literature. RESULTS: In
the base-case analysis, assuming a CAD prevalence of 39%
(range 18–64%) in the low to moderate risk patient population,
utilization of CTA in combination with CA lead to a cost savings
of $559 (USD) per patient (range $680–$416) compared to the
CA only diagnosis strategy. The hospital cost per diagnosis of
CAD was $12,483 (CTA + CA) (range $14,197–$11,900) and
$13,418 (CA only) (range $17,406–$12,100), and the propor-
tion of catheter lab diagnoses leading to PCI increased from 39%
(range 18–64%) to 73% (range 48–88%). CONCLUSION: Our
study suggests that CTA implementation in China could optimize
the patient population that undergoes invasive CA procedures
and provide cost-savings for Chinese hospitals.
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OBJECTIVE: To examine how found ‘obesity paradox’—a para-
doxical decrease in morbidity and mortality with increasing BMI
in subjects with cardiovascular disease (CVD)—relates to health
care-expenditures using Medical Expenditure Panel Survey
(MEPS). METHODS: We performed cross-sectional analyses of
11,385 adults from the 2005 MEPS, a national survey of nonin-
stitutionalized civilian population in the United States. Subjects
with CVD (coronary heart disease, myocardial infarction, stroke,
and hypertension) were determined from self-reports. Mean
expenditures per capita were estimated for NIH BMI categories
(under, normal, overweight, obese I, II, and III) using a two-part
exponential conditional model (ECM) adjusted for age, race,
wage, occupation, type of health insurance, degree level, and
smoking status. The ﬁrst part of the model was logistic regression
to predict the probability of incurring any expenditures. For the
second part, we used ECM since the log-scale expenditure data
was not leptokurtotic and was heteroscedastic. We performed
Box-Cox test and Park test to ﬁnd the link function and distri-
bution family. Average expenditures in 2005 U.S. dollars were
calculated by multiplying each person’s probability of incurring
any expense and expenditures. RESULTS: About 67% of sub-
jects with CVD (N = 2596) and 65% of subjects without CVD
(N = 8789) were overweight or obese. Using gamma distribution
with log link function, mean expenditures in CVD-group by BMI
categories were $3247, $3040, $3098, $2966, $3500, and $3375
(p = non-signiﬁcant). Those in subjects without CVD were
$1857, $2327, $2389, $2534, $3179, and $3783 (p < 0.001).
Age, smoking status, and Medicare were associated with
expenditures in CVD-group. CONCLUSION: Health care-
expenditures did not signiﬁcantly differ among BMI categories in
subjects with CVD whereas health care-expenditures were
increasing with BMI in subjects without CVD. This could be due
to the inﬂuence of CVD-care costs across weight categories in
CVD-group. We did not ﬁnd a obesity paradox in health care-
expenditures in subjects with CVD.
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OBJECTIVE: Few cost-of-illness studies in stroke have examined
the incremental impact of comorbid condition(s). The aim of this
study was to assess the costs of stroke management attributable
to stroke and comorbid conditions using data from the Medicare
program in the United States (U.S.). METHODS: Medicare
beneﬁciaries diagnosed with hemorrhagic (HS) and ischemic (IS)
stroke from 2002–2005 were identiﬁed from a 5% random
sample of Medicare outcomes and care database. Direct costs
were assessed from the perspective of the Medicare program.
Descriptive and multivariate analyses were performed. Data were
analyzed from one year prior to the index event through four
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